Search PubMed⌕ Search

Biomedical subjects

E Cameron

Publications and source records attributed to E Cameron.

At least 73 records · Page 4Linked to original sources
PubMed1983

Contribution of the haematocrit to the bleeding time.

Bleeding time, platelet count and haematocrit were performed in 64 normal, anaemic and polycythaemic subjects with normal renal function and platelet counts over 100 X 10(9)/1. There was a significant inverse correlation between the bleeding time and haematocrit (r = -0.47) and an inverse correlation of the haematocrit and platelet count (r = -0.46). We suggest that the effect of the haematocrit on the bleeding time could explain the shorter bleeding time in men compared to women, and the shorter bleeding time in subjects with arterial disease, in whom an increased haematocrit is commonly found.

Adult↗
PubMed1982

Vitamin C and cancer: an overview.

The outcome of every cancer illness is determined to a significant extent by the inherent resistance of the individual patient to his or her disease. There is increasing recognition that resistance to cancer depends, to a certain extent, upon the availability of certain nutritional factors, of which ascorbic acid appears to be the most important. Ascorbic acid protects against the destructive effects of malignant invasiveness by stabilizing the ground substance and enhancing collagen encapsulation. It is also involved in the mechanisms of both cell-mediated and humoral immunity including the production of interferon, and other factors either known or thought to be involved collectively in host resistance to neoplasia. There is also some recent evidence suggesting that ascorbate exerts a selective cytotoxic effect against malignant cells. All these observations indicate that supplemental ascorbate should be of some therapeutic value in the treatment of cancer. Clinical trials conducted over the last decade are briefly reviewed, and the balance of evidence supports this contention. It is predicted that in the not-to-distant future, supplemental ascorbate will attain an established place in all comprehensive cancer treatment regimes.

Adenocarcinoma, Scirrhous↗
PubMed1981

Locus of control as a predictor of attendance and success in the management of obesity.

For subjects attending a suburban self-help weight reduction program, successful weight reduction was associated with a relatively more 'internal' score. Although it may be expecting too much of the locus of control construct to provide confirmation of an overall theoretical basis or understanding to obesity, it would appear to warrant further evaluation with specific groups of obese subjects undergoing different weight reduction programs.

Adult↗
PubMed1979

Ascorbic acid and cancer: a review.

Host resistance to neoplastic growth and invasiveness is recognized to be an important factor in determining the occurrence, the progress, and the eventual outcome of every cancer illness. The factors involved in host resistance are briefly reviewed, and the relationship between these factors and ascorbic acid metabolism is presented in detail. It is shown that many factors involved in host resistance to neoplasia are significantly dependent upon the availability of ascorbate.

Animals↗
PubMed1978

Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer.

A study has been made of the survival times of 100 terminal cancer patients who were given supplemental ascorbate, usually 10 g/day, as part of their routine management and 1000 matched controls, similar patients who had received the same treatment except for the ascorbate. The two sets of patients were in part the same as those used in our earlier study [Cameron, E. & Pauling, L. (1976) Proc. Natl. Acad. Sci. USA 73, 3685-3689]. Tests confirm that the ascorbate-treated patients and the matched controls are representative subpopulations of the same population of "untreatable" patients. Survival times were measured not only from the date of "untreatability" but also from the precisely known date of first hospital attendance for the cancer that eventually reached the terminal stage. The ascorbate-treated patients were found to have a mean survival time about 300 days greater than that of the controls. Survival times greater than 1 yr after the date of untreatability were observed for 22% of the ascorbate-treated patients and for 0.4% of the controls. The mean survival time of these 22 ascorbate-treated patients is 2.4 yr after reaching the apparently terminal stage; 8 of the ascorbate-treated patients are still alive, with a mean survival time after untreatability of 3.5 yr.

Adult↗
PubMed1977

Cholera-like diarrhea in Canada. Report of a case associated with enterotoxigenic Escherichia coli and a toxin-producing Aeromonas hydrophila.

A 67-year-old Indian patient was admitted with an acute cholera-like illness. Toxigenic Escherichia coli producing both heat-stable and heat-labile enterotoxins grew from cultures of feces. In addition, an Aeromonas hydrophila producing a cytotoxic toxin was also isolated from this patient's feces. The unusual severity of this patient's illness may have resulted from coinfection with these two toxigenic organisms, although any role of the toxin produced by a hydrophila is speculative.

Aeromonas↗
PubMed1976

Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer.

Ascorbic acid metabolism is associated with a number of mechanisms known to be involved in host resistance to malignant disease. Cancer patients are significantly depleted of ascorbic acid, and in our opinion this demonstrable biochemical characteristic indicates a substantially increased requirement and utilization of this substance to potentiate these various host resistance factors. The results of a clinical trial are presented in which 100 terminal cancer patients were given supplemental ascorbate as part of their routine management. Their progress is compared to that of 1000 similar patients treated identically, but who received no supplemental ascorbate. The mean survival time is more than 4.2 times as great for the ascorbate subjects (more than 210 days) as for the controls (50 days). Analysis of the survival-time curves indicates that deaths occur for about 90% of the ascorbate-treated patients at one-third the rate for the controls and that the other 10% have a much greater survival time, averaging more than 20 times that for the controls. The results clearly indicate that this simple and safe form of medication is of definite value in the treatment of patients with advanced cancer.

Adult↗
PubMed1975

The orthomolecular treatment of cancer. III. Reticulum cell sarcoma: double complete regression induced by high-dose ascorbic acid therapy.

The response of a patient with histologically proven reticulum cell sarcoma to no treatment other than large doses of ascorbic acid is described. At the time of first diagnosis, the disease was widely disseminated, and a very dramatic regression of all parameters of disease activity was induced by the continuous administration of large doses of ascorbic acid. Reduction in dosage some months later coincided with reactivation of the disease process. The reinstitution of regular high-dose ascorbic acid therapy induced a second complete remission. The case report is illustrated by serial radiographs. The significance of the therapeutic response is briefly discussed in relation to general schemes of cancer management.

Adult↗
PubMed1973

Polarity and rate of transport of cyclic adenosine 3,5'-monophosphate in the coleoptile.

Transport of tritiated cyclic AMP in the coleoptile of oats (Avena sativa) and corn (Zea mays) is polar, with basipetal to acropetal ratios of 4.0 and 3.2, respectively. The rate of transport is approximately that of indoleacetic acid. The linear velocity of transport, however, is at least five times that of auxin. A loss in transport polarity of the nucleotide occurs in subapical tissues within several hours after decapitation of the coleoptile, accompanied by a decrease in transport rate. The loss in polarity is not reversed by exogenous auxin, but the reduction in transport is. Auxin also inhibits the uptake of cyclic AMP. Exogenous cyclic AMP is metabolized rapidly by coleoptile tissues. If cyclic AMP does have a cellular function in the coleoptile, its transport behavior is compatible with that of a hormone.

Journal Article↗